The authors showed that LDM temozolomide (1.77 mg/kg/day) was effective, from the beginning of the treatment, in hampering the growth of an orthotopic human U87MG-luc2 glioblastoma xenograft, implanted intracranially in Foxn1 nude mice. Here, FOXN1 is linked to glioblastoma.